CIDP, or chronic inflammatory demyelinating polyneuropathy, is a rare autoimmune disorder in which the body’s immune system attacks the protective coating around peripheral nerves. This damages the nerves’ ability to carry signals between the brain and the rest of the body, leading to progressive weakness and numbness that typically develops over weeks to months. It affects roughly 7 out of every 100,000 people, with a median age of diagnosis around 58.
How CIDP Damages Your Nerves
Your peripheral nerves are wrapped in a fatty insulating layer called myelin, which works like the rubber coating around an electrical wire. Myelin allows nerve signals to jump rapidly from one gap (called a node) to the next along the nerve fiber, rather than traveling slowly down the entire length. This is what makes your muscles respond quickly when your brain sends a command, and what lets you feel sensations in your fingers and toes almost instantly.
In CIDP, immune cells called macrophages physically strip away healthy myelin from the nerve fibers. They target areas around the nodes where signals jump, peeling back normal myelin layers and disrupting the architecture that holds the insulation in place. T-cells cross the blood-nerve barrier and trigger inflammation, while antibodies deposit directly onto myelinated nerve fibers. The result is patchy damage along the length of the nerve: signals slow down, get blocked entirely, or arrive scrambled. Over time, if the underlying nerve fiber itself sustains damage, some function may not fully recover even with treatment.
Symptoms and How They Develop
CIDP typically causes symmetric weakness and sensory changes in both arms and legs. The weakness often affects muscles close to the trunk (hips, thighs, shoulders, upper arms) as well as the hands and feet, which distinguishes it from many other neuropathies that start only in the extremities. Most people notice difficulty climbing stairs, getting up from a chair, or gripping objects. Numbness, tingling, and sometimes pain in the hands and feet are common sensory symptoms.
Reflexes at the knee, ankle, and other joints are typically reduced or absent because the reflex arc depends on fast signal conduction through myelinated nerves. Unlike Guillain-Barré syndrome (GBS), which comes on within two to four weeks and is often triggered by a recent infection, CIDP progresses more gradually over at least eight weeks. It can follow a steady worsening course, a stepwise pattern with periods of stability between declines, or a relapsing-remitting pattern where symptoms flare and then partially improve. Autonomic problems like blood pressure instability and cranial nerve involvement (facial weakness, difficulty swallowing) are uncommon in CIDP, which is another key difference from GBS.
How CIDP Is Diagnosed
Diagnosing CIDP involves piecing together clinical symptoms, nerve conduction testing, and sometimes a spinal tap. There is no single blood test that confirms the diagnosis, so the process can take time.
Nerve Conduction Studies
Nerve conduction studies are the cornerstone of diagnosis. These tests measure how fast electrical signals travel through your nerves and whether those signals are getting blocked along the way. In CIDP, doctors look for specific patterns of slowing: nerve signals traveling at least 30% slower than normal in two or more nerves, signals taking at least 50% longer than expected to reach the muscles from the stimulation point, or partial signal blockage where more than 30% of the signal strength is lost between two points on the same nerve. These patterns confirm that the problem is damage to myelin rather than to the nerve fibers themselves.
Spinal Fluid Analysis
A lumbar puncture (spinal tap) reveals a characteristic finding in about 90% of people with CIDP: elevated protein in the cerebrospinal fluid (above 45 mg/dL) without an increase in white blood cells. This combination, called cytoalbuminous dissociation, suggests that the nerve roots near the spinal cord are inflamed and leaking protein into the surrounding fluid, but without the kind of infection or cancer that would also raise the cell count.
Treatment Options
CIDP responds to immune-based therapies, which is actually one of the things that distinguishes it from other chronic neuropathies. The three first-line treatments are effective in 60% to 80% of patients.
Immunoglobulin Therapy
Intravenous immunoglobulin (IVIG) delivers a large dose of pooled antibodies that help calm the immune system’s attack on myelin. An initial course is typically given over two to five days. For people who respond well and need ongoing treatment, a subcutaneous version (SCIg) allows weekly self-injections at home rather than repeated hospital infusions. Many people prefer this option for the convenience and because it produces fewer of the headaches and fatigue that sometimes follow IV infusions.
Corticosteroids
Steroids suppress the broader immune response and reduce nerve inflammation. They’re often effective within weeks, though finding the right long-term dose takes careful adjustment. In one long-term study of steroid-treated patients, about 11% remained stable after stopping steroids entirely, and another 33% stayed well on just a small maintenance dose. Roughly 35% eventually needed additional immune-suppressing medications to stay stable. The trade-off with steroids is their side effect profile over months and years: weight gain, bone thinning, blood sugar changes, and mood effects.
Plasma Exchange
Plasma exchange (plasmapheresis) physically filters harmful antibodies out of the blood. A typical course involves four to six sessions over about 10 days, which can reduce circulating antibodies by 70% to 90%. It tends to produce rapid improvement and is particularly useful during severe flare-ups. However, the benefits fade faster than with other treatments, and relapse rates are higher compared with IVIG or steroids. For that reason, plasma exchange is used more often as a short-term rescue strategy than as long-term maintenance therapy.
Long-Term Outlook
CIDP is a chronic condition, but the word “chronic” doesn’t necessarily mean lifelong treatment for everyone. The disease follows different trajectories in different people. Some experience a single prolonged episode, respond to treatment, and eventually taper off therapy without relapse. Others have a relapsing-remitting course, needing treatment during flares but doing well between them. A smaller group has a steadily progressive form that requires ongoing immune therapy to maintain function.
The goal of long-term management is finding the lowest effective treatment dose. Many people on IVIG or SCIg undergo periodic “dose reduction trials,” where the dose or frequency is gradually decreased to see whether symptoms remain controlled. This helps avoid unnecessary treatment while catching relapses early. Early diagnosis and treatment matter: the longer myelin damage goes unchecked, the greater the risk of permanent nerve fiber injury underneath, which doesn’t respond as well to immune therapies. People who start treatment before significant axonal damage has occurred generally have better functional outcomes and are more likely to eventually come off treatment altogether.
How CIDP Differs From Similar Conditions
CIDP is sometimes confused with GBS because both are immune-mediated nerve diseases that cause weakness and reduced reflexes. The critical distinction is timing. GBS reaches its worst point within four weeks and then begins to recover, even without treatment. CIDP progresses beyond eight weeks and does not resolve on its own. Some people initially diagnosed with GBS who continue to worsen past the expected recovery window are reclassified as having CIDP, which changes the treatment approach significantly since CIDP responds to steroids while GBS does not.
CIDP also looks different from the more common peripheral neuropathies caused by diabetes or alcohol use. Those conditions primarily damage the nerve fibers themselves (axons) rather than the myelin coating, tend to affect only the feet and hands in a “stocking-glove” pattern, and do not cause the proximal weakness in hips and shoulders that is characteristic of CIDP. The nerve conduction patterns are different as well: diabetic neuropathy shows reduced signal strength, while CIDP shows slowed signal speed, reflecting the myelin-specific damage.